Michael Giordano

Michael F.
Giordano served as Senior Vice President & Head-Oncology Development at Bristol Myers Squibb Co. from 2012 to 2017.
He was Non-Executive Director at Achilles Therapeutics UK Ltd. from 2018 to 2021 and Independent Non-Executive Director at Achilles Therapeutics Plc from 2018 to 2024.
He held the position of Independent Director at Rapt Therapeutics, Inc. from 2018 to 2026.
He was Director at Epizyme, Inc. from 2018 to 2022 and Director at Oncovalent Therapeutics, Inc. from 2020 to 2023.
He worked as Assistant Professor at the National Institutes of Health and Weill Cornell Medicine.
Dr. Giordano completed undergraduate studies at The Johns Hopkins University and earned a doctorate from Weill Cornell Medicine.